Easywell Biomedicals, Inc. (TPEX:1799)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.90
-0.25 (-0.78%)
At close: Feb 26, 2026
-52.88%
Market Cap 3.98B
Revenue (ttm) 588.89M
Net Income (ttm) -64.44M
Shares Out 124.69M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 143,694
Average Volume 115,797
Open 32.10
Previous Close 32.15
Day's Range 31.70 - 32.10
52-Week Range 30.70 - 83.70
Beta 0.11
RSI 40.28
Earnings Date Mar 27, 2026

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angi... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 1799
Full Company Profile

Financial Performance

In 2024, Easywell Biomedicals's revenue was 540.44 million, an increase of 98.96% compared to the previous year's 271.63 million. Losses were -97.47 million, -32.70% less than in 2023.

Financial Statements

News

There is no news available yet.